BACKGROUND: Bacteraemia is an important cause of morbidity and mortality in critically ill children. Our objective was to assess whether daily bathing in chlorhexidine gluconate (CHG) compared with standard bathing practices would reduce bacteraemia in critically ill children. METHODS: In an unmasked, cluster-randomised, two-period crossover trial, ten paediatric intensive-care units at five hospitals in the USA were randomly assigned a daily bathing routine for admitted patients older than 2 months, either standard bathing practices or using a cloth impregnated with 2% CHG, for a 6-month period. Units switched to the alternative bathing method for a second 6-month period. 6482 admissions were screened for eligibility. The primary outcome was an episode of bacteraemia. We did intention-to-treat (ITT) and per-protocol (PP) analyses. This study is registered with ClinicalTrials.gov (identifier NCT00549393). FINDINGS:1521 admitted patients were excluded because their length of stay was less than 2 days, and 14 refused to participate. 4947 admissions were eligible for analysis. In the ITT population, a non-significant reduction in incidence of bacteraemia was noted with CHG bathing (3·52 per 1000 days, 95% CI 2·64-4·61) compared with standard practices (4·93 per 1000 days, 3·91-6·15; adjusted incidence rate ratio [aIRR] 0·71, 95% CI 0·42-1·20). In the PP population, incidence of bacteraemia was lower in patients receiving CHG bathing (3·28 per 1000 days, 2·27-4·58) compared with standard practices (4·93 per 1000 days, 3·91-6·15; aIRR 0·64, 0·42-0·98). No serious study-related adverse events were recorded, and the incidence of CHG-associated skin reactions was 1·2 per 1000 days (95% CI 0·60-2·02). INTERPRETATION:Critically ill children receivingdaily CHG bathing had a lower incidence of bacteraemia compared with those receiving a standard bathing routine. Furthermore, the treatment was well tolerated. FUNDING: Sage Products, US National Institutes of Health.
RCT Entities:
BACKGROUND:Bacteraemia is an important cause of morbidity and mortality in critically ill children. Our objective was to assess whether daily bathing in chlorhexidine gluconate (CHG) compared with standard bathing practices would reduce bacteraemia in critically ill children. METHODS: In an unmasked, cluster-randomised, two-period crossover trial, ten paediatric intensive-care units at five hospitals in the USA were randomly assigned a daily bathing routine for admitted patients older than 2 months, either standard bathing practices or using a cloth impregnated with 2% CHG, for a 6-month period. Units switched to the alternative bathing method for a second 6-month period. 6482 admissions were screened for eligibility. The primary outcome was an episode of bacteraemia. We did intention-to-treat (ITT) and per-protocol (PP) analyses. This study is registered with ClinicalTrials.gov (identifier NCT00549393). FINDINGS: 1521 admitted patients were excluded because their length of stay was less than 2 days, and 14 refused to participate. 4947 admissions were eligible for analysis. In the ITT population, a non-significant reduction in incidence of bacteraemia was noted with CHG bathing (3·52 per 1000 days, 95% CI 2·64-4·61) compared with standard practices (4·93 per 1000 days, 3·91-6·15; adjusted incidence rate ratio [aIRR] 0·71, 95% CI 0·42-1·20). In the PP population, incidence of bacteraemia was lower in patients receiving CHG bathing (3·28 per 1000 days, 2·27-4·58) compared with standard practices (4·93 per 1000 days, 3·91-6·15; aIRR 0·64, 0·42-0·98). No serious study-related adverse events were recorded, and the incidence of CHG-associated skin reactions was 1·2 per 1000 days (95% CI 0·60-2·02). INTERPRETATION: Critically ill children receiving daily CHG bathing had a lower incidence of bacteraemia compared with those receiving a standard bathing routine. Furthermore, the treatment was well tolerated. FUNDING: Sage Products, US National Institutes of Health.
Authors: John C O'Horo; Germana L M Silva; L Silvia Munoz-Price; Nasia Safdar Journal: Infect Control Hosp Epidemiol Date: 2012-01-25 Impact factor: 3.254
Authors: Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren Journal: Clin Infect Dis Date: 2009-07-01 Impact factor: 9.079
Authors: Jonathan R Edwards; Kelly D Peterson; Yi Mu; Shailendra Banerjee; Katherine Allen-Bridson; Gloria Morrell; Margaret A Dudeck; Daniel A Pollock; Teresa C Horan Journal: Am J Infect Control Date: 2009-12 Impact factor: 2.918
Authors: Marlene R Miller; Michael Griswold; J Mitchell Harris; Gayane Yenokyan; W Charles Huskins; Michele Moss; Tom B Rice; Debra Ridling; Deborah Campbell; Peter Margolis; Stephen Muething; Richard J Brilli Journal: Pediatrics Date: 2010-01-11 Impact factor: 7.124
Authors: Yuri F van der Heijden; Geraldine Miller; Patty W Wright; Bryan E Shepherd; Titus L Daniels; Thomas R Talbot Journal: Infect Control Hosp Epidemiol Date: 2011-06 Impact factor: 3.254
Authors: Joseph Schulman; Rachel Stricof; Timothy P Stevens; Michael Horgan; Kathleen Gase; Ian R Holzman; Robert I Koppel; Suhas Nafday; Kathleen Gibbs; Robert Angert; Aryeh Simmonds; Susan A Furdon; Lisa Saiman Journal: Pediatrics Date: 2011-02-21 Impact factor: 7.124
Authors: Matthew F Niedner; W Charles Huskins; Elizabeth Colantuoni; John Muschelli; J Mitchell Harris; Tom B Rice; Richard J Brilli; Marlene R Miller Journal: Infect Control Hosp Epidemiol Date: 2011-10-13 Impact factor: 3.254
Authors: Andrew Lee; Robert Harlan; Autumn R Breaud; Kathleen Speck; Trish M Perl; William Clarke; Aaron M Milstone Journal: Infect Control Hosp Epidemiol Date: 2011-04 Impact factor: 3.254
Authors: Alicia I Hidron; Jonathan R Edwards; Jean Patel; Teresa C Horan; Dawn M Sievert; Daniel A Pollock; Scott K Fridkin Journal: Infect Control Hosp Epidemiol Date: 2008-11 Impact factor: 3.254
Authors: Mark J Peters; Andrew Argent; Marino Festa; Stéphane Leteurtre; Jefferson Piva; Ann Thompson; Douglas Willson; Pierre Tissières; Marisa Tucci; Jacques Lacroix Journal: Intensive Care Med Date: 2017-03-17 Impact factor: 17.440
Authors: Melissa A Viray; James C Morley; Craig M Coopersmith; Marin H Kollef; Victoria J Fraser; David K Warren Journal: Infect Control Hosp Epidemiol Date: 2014-01-24 Impact factor: 3.254